Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antigen peptide chain group for treating tumor and application thereof to medicine

An antigen peptide and drug technology, applied in the field of malignant tumor bioimmune drugs, can solve problems such as hearing loss, side effects, blurred vision, etc., and achieve the effect of small incidence of side effects, killing tumor cells, and obvious changes.

Inactive Publication Date: 2018-08-24
天津亨佳生物科技发展有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are many methods of biological immunotherapy for tumors, including common CIK cell immunotherapy, DC drug therapy, etc., but the therapeutic effect is not significant, and the survival rate of patients has not been significantly improved
In addition, immune cells stimulated by non-mutated tumor highly expressed proteins have been studied for anti-tumor immune responses, but due to their non-specific expression, there are side effects, including blurred vision, hearing loss, rash, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigen peptide chain group for treating tumor and application thereof to medicine
  • Antigen peptide chain group for treating tumor and application thereof to medicine
  • Antigen peptide chain group for treating tumor and application thereof to medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Patient A, female, 66 years old, lung adenocarcinoma, liver metastases, clinical stage IV, progression after 6 cycles of vinorelbine monotherapy chemotherapy, targeted drug resistance, lung lesion biopsy, whole exome sequencing and After the HLA typing chip detection, the patient carried the 19DEL mutation, and the HLA typing was HLA-A: A*2103A*3201; HLA-B: B*3217B*3102; HLA-C: C*0302C*0512; HLA-DQB1: DQB1*0201DQB1*1221; HLA-DRB1: DRB1*0201DRB1*0601.

[0028] Use the specific tumor antigen peptide chain SEQ ID No: 1 of the present invention for treatment once a week for a total of 12 weeks. Detect the secretion of specific CD8+Tetramer+T cells by spot detection before and after the injection of the antigen peptide chain group (hereinafter referred to as "medication"), and observe the changes in tumor size 12 weeks before and after the administration by imaging. The results are as follows: figure 1 and figure 2 shown.

[0029] figure 1 HLA*A3101-HVKITDFGR Tetramer s...

Embodiment 2

[0033] Patient B, female, 62 years old, lung adenocarcinoma, pleural metastases, no indication for surgery, treated with gemcitabine + carboplatin intravenous chemotherapy for 6 weeks, progressed after 2 cycles of docetaxel chemotherapy, and progressed after local interventional therapy. After whole exome sequencing and HLA typing chip detection, the patient carried a 19DEL mutation, and the HLA typing was HLA-A: A*0303A*6501; HLA-B: B*0301B*3201; HLA-C: C*0201C *0501; HLA-DQB1: DQB1*0202DQB1*0130; HLA-DRB1: DRB1*0312DRB1*1222.

[0034] Combination therapy with the antigenic peptide chain SEQ ID No: 2 for treating tumors of the present invention, once a week, for 12 weeks in total.

[0035] The changes in the size of lung tumors before and after treatment are as follows: image 3 shown by image 3 It can be seen that before drug treatment, the size of the tumor in the lower lobe of the left lung was 4cm×6cm ( image 3 -A); After 12 weeks of drug treatment, the tumor in the ...

Embodiment 3-100

[0037] Example 3-100 Cancer patients of different types and degrees were taken. After whole exome sequencing and HLA typing chip detection, the patients were all patients with 19DEL mutation, and they were treated with combinations of different antigen peptide chain groups. , once a week for 12 weeks. The results of HLA*A3101-HVKITDFGR Tetramer staining in Example 3-100 and the changes in the size of lung tumors before and after treatment are similar to those in Example 1-2, and will not be repeated here due to space limitations. The above results can all show that the antigen peptide chain group of the present invention can induce dendritic cells that produce tumors, and dendritic cells as antigen-presenting cells can present antigen information to T cells, interact with T cells, and cause T cells to produce tumors. It specifically kills tumor cells, plays a role in killing tumor cells, and the effect is obvious.

[0038] During the treatment of Examples 1-100, ELISA was use...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antigen peptide chain group for tumor individualized biological immunotherapy and application thereof to medicine. The antigen peptide chain group for treating tumor comprises any one of SEQ ID No: 1 to No: 100 or a combination of at least two amino acid sequences. The antigen peptide chain group provided by the invention can induce dendritic cells that produce tumor, sothat the dendritic cells as antigen-presenting cells can present antigen information to T cells, thereby interacting with the T cells to enable the T cells to generate specificity to kill tumor cells, and realizing the effect of killing the tumor cells.

Description

technical field [0001] The invention belongs to the technical field of malignant tumor bioimmune drugs, and in particular relates to an antigen peptide chain group for individualized biological immunotherapy of tumors and its application in medicine. Background technique [0002] At present, the global incidence of malignant tumors is increasing, the mortality rate is high, and the prognosis is poor. The National Cancer Prevention and Research Office of the National Cancer Center released the largest comprehensive analysis of cancer survival data in China in the International Journal of Cancer. The data shows that the 5-year survival rate of cancer in China is 30.9%, which is far lower than that of developed countries; at the same time, the survival rate of rural patients is only half of urban patients. In developed countries, prostate cancer and breast cancer account for the majority. In China, cancers such as lung cancer, gastric cancer, and liver cancer are more common, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C07K7/08A61K39/00A61P35/00
CPCC07K7/06A61K39/0011A61P35/00C07K7/08
Inventor 刘玉强霍冲
Owner 天津亨佳生物科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com